IBDEI09M ; ; 20-MAY-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;OCT 15, 2014
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,4444,1,3,0)
 ;;=3^583.81
 ;;^UTILITY(U,$J,358.3,4444,1,4,0)
 ;;=4^SECONDARY GLOMERONEPHRITIS
 ;;^UTILITY(U,$J,358.3,4444,2)
 ;;=^82243
 ;;^UTILITY(U,$J,358.3,4445,0)
 ;;=583.9^^37^430^6
 ;;^UTILITY(U,$J,358.3,4445,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,4445,1,3,0)
 ;;=3^583.9
 ;;^UTILITY(U,$J,358.3,4445,1,4,0)
 ;;=4^NEPHRITIS NOS
 ;;^UTILITY(U,$J,358.3,4445,2)
 ;;=^83446
 ;;^UTILITY(U,$J,358.3,4446,0)
 ;;=710.0^^37^430^17
 ;;^UTILITY(U,$J,358.3,4446,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,4446,1,3,0)
 ;;=3^710.0
 ;;^UTILITY(U,$J,358.3,4446,1,4,0)
 ;;=4^SYSTEMIC LUPUS
 ;;^UTILITY(U,$J,358.3,4446,2)
 ;;=^72159^582.81
 ;;^UTILITY(U,$J,358.3,4447,0)
 ;;=582.89^^37^431^2
 ;;^UTILITY(U,$J,358.3,4447,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,4447,1,3,0)
 ;;=3^582.89
 ;;^UTILITY(U,$J,358.3,4447,1,4,0)
 ;;=4^NEPHRITIS INTERSTITIAL,CHR
 ;;^UTILITY(U,$J,358.3,4447,2)
 ;;=^270349
 ;;^UTILITY(U,$J,358.3,4448,0)
 ;;=580.89^^37^431^1
 ;;^UTILITY(U,$J,358.3,4448,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,4448,1,3,0)
 ;;=3^580.89
 ;;^UTILITY(U,$J,358.3,4448,1,4,0)
 ;;=4^NEPHRITIS INTERSTITIAL,AC
 ;;^UTILITY(U,$J,358.3,4448,2)
 ;;=^270340
 ;;^UTILITY(U,$J,358.3,4449,0)
 ;;=583.89^^37^431^3
 ;;^UTILITY(U,$J,358.3,4449,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,4449,1,3,0)
 ;;=3^583.89
 ;;^UTILITY(U,$J,358.3,4449,1,4,0)
 ;;=4^NEPHROPATHY,ANALGESIC
 ;;^UTILITY(U,$J,358.3,4449,2)
 ;;=^83443
 ;;^UTILITY(U,$J,358.3,4450,0)
 ;;=042.^^37^432^1
 ;;^UTILITY(U,$J,358.3,4450,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,4450,1,3,0)
 ;;=3^042.
 ;;^UTILITY(U,$J,358.3,4450,1,4,0)
 ;;=4^AIDS
 ;;^UTILITY(U,$J,358.3,4450,2)
 ;;=^266500
 ;;^UTILITY(U,$J,358.3,4451,0)
 ;;=581.1^^37^432^2
 ;;^UTILITY(U,$J,358.3,4451,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,4451,1,3,0)
 ;;=3^581.1
 ;;^UTILITY(U,$J,358.3,4451,1,4,0)
 ;;=4^NEPHRITIS EPIMEMBRANOUS (FSGS)
 ;;^UTILITY(U,$J,358.3,4451,2)
 ;;=^270344
 ;;^UTILITY(U,$J,358.3,4452,0)
 ;;=581.2^^37^432^3
 ;;^UTILITY(U,$J,358.3,4452,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,4452,1,3,0)
 ;;=3^581.2
 ;;^UTILITY(U,$J,358.3,4452,1,4,0)
 ;;=4^NEPHROSIS MEMBRANOPROL
 ;;^UTILITY(U,$J,358.3,4452,2)
 ;;=^270345
 ;;^UTILITY(U,$J,358.3,4453,0)
 ;;=581.3^^37^432^4
 ;;^UTILITY(U,$J,358.3,4453,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,4453,1,3,0)
 ;;=3^581.3
 ;;^UTILITY(U,$J,358.3,4453,1,4,0)
 ;;=4^NEPHROSIS,MINIMAL CHANGE
 ;;^UTILITY(U,$J,358.3,4453,2)
 ;;=^82320
 ;;^UTILITY(U,$J,358.3,4454,0)
 ;;=581.9^^37^432^5
 ;;^UTILITY(U,$J,358.3,4454,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,4454,1,3,0)
 ;;=3^581.9
 ;;^UTILITY(U,$J,358.3,4454,1,4,0)
 ;;=4^NEPHROTIC SYNDROME NOS
 ;;^UTILITY(U,$J,358.3,4454,2)
 ;;=^82357
 ;;^UTILITY(U,$J,358.3,4455,0)
 ;;=446.0^^37^432^6
 ;;^UTILITY(U,$J,358.3,4455,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,4455,1,3,0)
 ;;=3^446.0
 ;;^UTILITY(U,$J,358.3,4455,1,4,0)
 ;;=4^POLYARTERITIS
 ;;^UTILITY(U,$J,358.3,4455,2)
 ;;=^91874
 ;;^UTILITY(U,$J,358.3,4456,0)
 ;;=581.81^^37^432^7
 ;;^UTILITY(U,$J,358.3,4456,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,4456,1,3,0)
 ;;=3^581.81
 ;;^UTILITY(U,$J,358.3,4456,1,4,0)
 ;;=4^SECONDARY NEPHROTIC SYNDROME
 ;;^UTILITY(U,$J,358.3,4456,2)
 ;;=^270346
 ;;^UTILITY(U,$J,358.3,4457,0)
 ;;=710.0^^37^432^8
 ;;^UTILITY(U,$J,358.3,4457,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,4457,1,3,0)
 ;;=3^710.0
 ;;^UTILITY(U,$J,358.3,4457,1,4,0)
 ;;=4^SYSTEMIC LUPUS
 ;;^UTILITY(U,$J,358.3,4457,2)
 ;;=^72159
 ;;^UTILITY(U,$J,358.3,4458,0)
 ;;=596.0^^37^433^1
 ;;^UTILITY(U,$J,358.3,4458,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,4458,1,3,0)
 ;;=3^596.0
